A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO4602522 ADDED TO THE BACKGROUND THERAPY OF THE ACETYLCHOLINESTERASE INHIBITORS DONEPEZIL OR RIVASTIGMINE IN PATIENTS WITH MODERATE SEVERITY ALZHEIMER'S DISEASE
What is the purpose of this trial?
The purpose of this study is to investigate the safety and efficacy of RO4602522 as an add-on treatment to current treatments in patients with moderate Alzheimer's disease.
- 50 Years - 90 Years
- Hoffman-La Roche
- Last Updated:
- Study HIC#: